Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effect of hydroxychloroquine on the cardiac ventricular repolarization : A randomized clinical trial. / Eveleens Maarse, Boukje C.; Graff, Claus; Kanters, Jørgen K.; van Esdonk, Michiel J.; Kemme, Michiel J.B.; in 't Veld, Aliede E.; Jansen, Manon A.A.; Moerland, Matthijs; Gal, Pim.

In: British Journal of Clinical Pharmacology, Vol. 88, No. 3, 03.2022, p. 1054-1062.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Eveleens Maarse, BC, Graff, C, Kanters, JK, van Esdonk, MJ, Kemme, MJB, in 't Veld, AE, Jansen, MAA, Moerland, M & Gal, P 2022, 'Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial', British Journal of Clinical Pharmacology, vol. 88, no. 3, pp. 1054-1062. https://doi.org/10.1111/bcp.15013

APA

Eveleens Maarse, B. C., Graff, C., Kanters, J. K., van Esdonk, M. J., Kemme, M. J. B., in 't Veld, A. E., Jansen, M. A. A., Moerland, M., & Gal, P. (2022). Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. British Journal of Clinical Pharmacology, 88(3), 1054-1062. https://doi.org/10.1111/bcp.15013

Vancouver

Eveleens Maarse BC, Graff C, Kanters JK, van Esdonk MJ, Kemme MJB, in 't Veld AE et al. Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. British Journal of Clinical Pharmacology. 2022 Mar;88(3):1054-1062. https://doi.org/10.1111/bcp.15013

Author

Eveleens Maarse, Boukje C. ; Graff, Claus ; Kanters, Jørgen K. ; van Esdonk, Michiel J. ; Kemme, Michiel J.B. ; in 't Veld, Aliede E. ; Jansen, Manon A.A. ; Moerland, Matthijs ; Gal, Pim. / Effect of hydroxychloroquine on the cardiac ventricular repolarization : A randomized clinical trial. In: British Journal of Clinical Pharmacology. 2022 ; Vol. 88, No. 3. pp. 1054-1062.

Bibtex

@article{cec85c72ac71457cb2c0bf228caffa56,
title = "Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial",
abstract = "Aims: Hydroxychloroquine has been suggested as possible treatment for severe acute respiratory syndrome-coronavirus-2. Studies reported an increased risk of QTcF-prolongation after treatment with hydroxychloroquine. The aim of this study was to analyse the concentration-dependent effects of hydroxychloroquine on the ventricular repolarization, including QTcF-duration and T-wave morphology. Methods: Twenty young (≤30 y) and 20 elderly (65–75 y) healthy male subjects were included. Subjects were randomized to receive either a total dose of 2400 mg hydroxychloroquine over 5 days, or placebo (ratio 1:1). Follow-up duration was 28 days. Electrocardiograms (ECGs) were recorded as triplicate at baseline and 4 postdose single recordings, followed by hydroxychloroquine concentration measurements. ECG intervals (RR, QRS, PR, QTcF, J-Tpc, Tp-Te) and T-wave morphology, measured with the morphology combination score, were analysed with a prespecified linear mixed effects concentration–effect model. Results: There were no significant associations between hydroxychloroquine concentrations and ECG characteristics, including RR-, QRS- and QTcF-interval (P =.09,.34,.25). Mean ΔΔQTcF-interval prolongation did not exceed 5 ms and the upper limit of the 90% confidence interval did not exceed 10 ms at the highest measured concentrations (200 ng/mL). There were no associations between hydroxychloroquine concentration and the T-wave morphology (P =.34 for morphology combination score). There was no significant effect of age group on ECG characteristics. Conclusion: In this study, hydroxychloroquine did not affect ventricular repolarization, including the QTcF-interval and T-wave morphology, at plasma concentrations up to 200 ng/mL. Based on this analysis, hydroxychloroquine does not appear to increase the risk of QTcF-induced arrhythmias.",
keywords = "cardiac ventricular repolarization, concentration–effect analysis, electrocardiogram, hydroxychloroquine, QT-interval",
author = "{Eveleens Maarse}, {Boukje C.} and Claus Graff and Kanters, {J{\o}rgen K.} and {van Esdonk}, {Michiel J.} and Kemme, {Michiel J.B.} and {in 't Veld}, {Aliede E.} and Jansen, {Manon A.A.} and Matthijs Moerland and Pim Gal",
note = "Funding Information: The study was funded by the Centre for Human Drug Research, Leiden, The Netherlands. Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.",
year = "2022",
month = mar,
doi = "10.1111/bcp.15013",
language = "English",
volume = "88",
pages = "1054--1062",
journal = "British Journal of Clinical Pharmacology, Supplement",
issn = "0264-3774",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Effect of hydroxychloroquine on the cardiac ventricular repolarization

T2 - A randomized clinical trial

AU - Eveleens Maarse, Boukje C.

AU - Graff, Claus

AU - Kanters, Jørgen K.

AU - van Esdonk, Michiel J.

AU - Kemme, Michiel J.B.

AU - in 't Veld, Aliede E.

AU - Jansen, Manon A.A.

AU - Moerland, Matthijs

AU - Gal, Pim

N1 - Funding Information: The study was funded by the Centre for Human Drug Research, Leiden, The Netherlands. Publisher Copyright: © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

PY - 2022/3

Y1 - 2022/3

N2 - Aims: Hydroxychloroquine has been suggested as possible treatment for severe acute respiratory syndrome-coronavirus-2. Studies reported an increased risk of QTcF-prolongation after treatment with hydroxychloroquine. The aim of this study was to analyse the concentration-dependent effects of hydroxychloroquine on the ventricular repolarization, including QTcF-duration and T-wave morphology. Methods: Twenty young (≤30 y) and 20 elderly (65–75 y) healthy male subjects were included. Subjects were randomized to receive either a total dose of 2400 mg hydroxychloroquine over 5 days, or placebo (ratio 1:1). Follow-up duration was 28 days. Electrocardiograms (ECGs) were recorded as triplicate at baseline and 4 postdose single recordings, followed by hydroxychloroquine concentration measurements. ECG intervals (RR, QRS, PR, QTcF, J-Tpc, Tp-Te) and T-wave morphology, measured with the morphology combination score, were analysed with a prespecified linear mixed effects concentration–effect model. Results: There were no significant associations between hydroxychloroquine concentrations and ECG characteristics, including RR-, QRS- and QTcF-interval (P =.09,.34,.25). Mean ΔΔQTcF-interval prolongation did not exceed 5 ms and the upper limit of the 90% confidence interval did not exceed 10 ms at the highest measured concentrations (200 ng/mL). There were no associations between hydroxychloroquine concentration and the T-wave morphology (P =.34 for morphology combination score). There was no significant effect of age group on ECG characteristics. Conclusion: In this study, hydroxychloroquine did not affect ventricular repolarization, including the QTcF-interval and T-wave morphology, at plasma concentrations up to 200 ng/mL. Based on this analysis, hydroxychloroquine does not appear to increase the risk of QTcF-induced arrhythmias.

AB - Aims: Hydroxychloroquine has been suggested as possible treatment for severe acute respiratory syndrome-coronavirus-2. Studies reported an increased risk of QTcF-prolongation after treatment with hydroxychloroquine. The aim of this study was to analyse the concentration-dependent effects of hydroxychloroquine on the ventricular repolarization, including QTcF-duration and T-wave morphology. Methods: Twenty young (≤30 y) and 20 elderly (65–75 y) healthy male subjects were included. Subjects were randomized to receive either a total dose of 2400 mg hydroxychloroquine over 5 days, or placebo (ratio 1:1). Follow-up duration was 28 days. Electrocardiograms (ECGs) were recorded as triplicate at baseline and 4 postdose single recordings, followed by hydroxychloroquine concentration measurements. ECG intervals (RR, QRS, PR, QTcF, J-Tpc, Tp-Te) and T-wave morphology, measured with the morphology combination score, were analysed with a prespecified linear mixed effects concentration–effect model. Results: There were no significant associations between hydroxychloroquine concentrations and ECG characteristics, including RR-, QRS- and QTcF-interval (P =.09,.34,.25). Mean ΔΔQTcF-interval prolongation did not exceed 5 ms and the upper limit of the 90% confidence interval did not exceed 10 ms at the highest measured concentrations (200 ng/mL). There were no associations between hydroxychloroquine concentration and the T-wave morphology (P =.34 for morphology combination score). There was no significant effect of age group on ECG characteristics. Conclusion: In this study, hydroxychloroquine did not affect ventricular repolarization, including the QTcF-interval and T-wave morphology, at plasma concentrations up to 200 ng/mL. Based on this analysis, hydroxychloroquine does not appear to increase the risk of QTcF-induced arrhythmias.

KW - cardiac ventricular repolarization

KW - concentration–effect analysis

KW - electrocardiogram

KW - hydroxychloroquine

KW - QT-interval

U2 - 10.1111/bcp.15013

DO - 10.1111/bcp.15013

M3 - Journal article

C2 - 34327732

AN - SCOPUS:85113718166

VL - 88

SP - 1054

EP - 1062

JO - British Journal of Clinical Pharmacology, Supplement

JF - British Journal of Clinical Pharmacology, Supplement

SN - 0264-3774

IS - 3

ER -

ID: 306683725